Contraline, Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on February 4, 2026 - 16:00 GMT

Contraline and Population Council Execute Global Exclusive License Agreement for NES/T Male Contraception Gel

Contraline Set to Launch a Historic Phase 3 Clinical Program in Male Contraception NEW YORK, NY, UNITED STATES, February 4, 2026 /⁨EINPresswire.com⁩/ -- Contraline Inc., a clinical-stage biotechnology company, and the Population Council, an international …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on July 30, 2025 - 13:00 GMT

Contraline Exercises License Option for NES/T, the First Male Contraceptive to Reach Late-Stage Development

CHARLOTTESVILLE, VA, UNITED STATES, July 30, 2025 /⁨EINPresswire.com⁩/ -- Contraline, Inc., a clinical-stage biotechnology company developing novel male contraceptives, today announced that it has exercised its option to exclusively license the Nestorone®/ …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on April 24, 2025 - 12:00 GMT

Contraline Announces 24-Month Safety and Efficacy Results from First-in-Human Trial of ADAM™

CHARLOTTESVILLE, VA, UNITED STATES, April 24, 2025 /⁨EINPresswire.com⁩/ -- Contraline, a clinical-stage male contraception company, today announced that participants in the First-in-Human clinical trial of ADAM™ (“The ADAM Study”) have reached a critical …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on April 15, 2025 - 12:02 GMT

Contraline Secures 15th Issued Patent, Reinforcing IP Leadership in Male Contraception

CHARLOTTESVILLE, VA, UNITED STATES, April 15, 2025 /⁨EINPresswire.com⁩/ -- Contraline, Inc., the leading innovator in male contraception, today announced the issuance of its 15th U.S. patent, further advancing the company’s mission to develop a new …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on July 9, 2024 - 13:00 GMT

Contraline's First In-Human Trial Shows Safety with 12-Month Efficacy Signals of the ADAM™ Male Contraceptive Device

CHARLOTTESVILLE, VA, UNITED STATES, July 9, 2024 /⁨EINPresswire.com⁩/ -- Contraline, a clinical-stage biotechnology company, has announced promising initial safety and efficacy results from its First-in-Human clinical trial. The trial, which is evaluating …

Distribution channels: Healthcare & Pharmaceuticals Industry ...